Research & Regulatory News

The Trial Where Glucose-Dependence Shows Up in Numbers

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

SURPASS-4 randomised 2,002 participants with type 2 diabetes and increased cardiovascular risk to tirzepatide or insulin glargine over 52 weeks. Del Prato and colleagues published it in the Lancet in November 2021, and its sulfonylurea subgroup isolates the glucose-dependence effect.

Key facts

Published
Lancet, 13 November 2021 (PMID 34672967)
Randomised
2,002
Dosed
1,995 (glargine n=1,000)
Design
Randomised, open-label, parallel-group
HbA1c at 52 weeks
−2.43% (10 mg), −2.58% (15 mg) vs −1.44%
Hypoglycaemia overall
6-9% vs 19%
Without sulfonylurea
1-3% vs 16%
MACE-4
HR 0.74 (95% CI 0.51-1.08)

Why comparing against insulin is the informative design

Insulin lowers glucose regardless of what glucose is doing; it is the archetype of a glucose-independent agent. Setting an incretin against it puts the two mechanisms side by side in one population, which is where a difference in hypoglycaemia should appear if glucose-dependence means anything.

The headline glycaemic result

At 52 weeks, mean HbA1c fell 2.43% on tirzepatide 10 mg and 2.58% on 15 mg, against 1.44% with glargine. So the incretin lowered glucose substantially more than insulin titrated in a trial setting, which makes the hypoglycaemia comparison more striking rather than less.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

The subgroup that carries the mechanism

Hypoglycaemia, defined as glucose below 54 mg/dL or clinically severe, occurred in 6 to 9% on tirzepatide against 19% on glargine. Among participants not taking a sulfonylurea the figures were 1 to 3% against 16%. That split isolates the effect: remove the glucose-independent oral agent and the incretin's rate falls to near-negligible while insulin's barely moves.

What the sulfonylurea contribution demonstrates

That the residual hypoglycaemia seen with the incretin was largely attributable to something else in the regimen. A compound showing 1 to 3% alone and 6 to 9% in combination has not become more dangerous; the combination has. This is as clear a natural demonstration of glucose-dependence as trial data offers.

The cardiovascular finding

Adjudicated MACE-4 events (cardiovascular death, myocardial infarction, stroke, hospitalisation for unstable angina) occurred in 109 participants, with a hazard ratio of 0.74 and a confidence interval from 0.51 to 1.08. The interval crosses one, so this establishes no excess risk rather than demonstrating benefit. Sixty deaths occurred, 25 on tirzepatide and 35 on glargine.

The design limitation

Open-label. Blinding an injectable titrated against glucose readings is impractical, and participants and investigators knew their assignment. That is a real limitation for subjectively reported outcomes, though less consequential for a laboratory-defined endpoint like glucose below a threshold.

What this does not concern

Research material. Both compounds are licensed medicines administered in a registered trial under clinical supervision, in people with type 2 diabetes and elevated cardiovascular risk. Nothing supplied on this site affects blood glucose or is an alternative to any diabetes treatment.

Quick reference

TirzepatideGlargine
HbA1c change, 15 mg−2.58%−1.44%
Hypoglycaemia, overall6-9%19%
Hypoglycaemia, no sulfonylurea1-3%16%
Deaths25 (3%)35 (4%)

Frequently asked questions

What did SURPASS-4 compare?

Tirzepatide against insulin glargine in 2,002 randomised participants with type 2 diabetes and increased cardiovascular risk, over 52 weeks.

Why is the sulfonylurea subgroup important?

Without a sulfonylurea, tirzepatide hypoglycaemia was 1-3% against glargine's 16%, isolating the glucose-independent agent as the source of most of the residual risk.

Did it show cardiovascular benefit?

No. The MACE-4 hazard ratio was 0.74 with an interval from 0.51 to 1.08, which crosses one, establishing no excess risk rather than benefit.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More Research & Regulatory News articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.